Genetic analysis of primary lung interdigitating dendritic cell sarcomas
The rarest lung dendritic cell tumors harbor actionable genetic changes in nearly every case, opening a first druggable roadmap for this entity.
Whole-exome and shallow whole-genome sequencing of 9 primary lung interdigitating dendritic cell sarcomas—one of the rarest hematological tumor types—reveals a heterogeneous genetic landscape with actionable alterations (EGFR, MYC, ERBB2, ATM amplifications/losses) in virtually all cases. Chromosome 17 gains appear as a near-universal feature independent of grade, and high-grade tumors show elevated TMB, collectively establishing the first druggable genomic roadmap for this rare entity.
What the study was
- Study design
- Case series with WES + shallow WGS
- Population
- Primary lung interdigitating dendritic cell sarcoma patients
- Sample size
- 9
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- The Journal of Pathology
Why it surfaced
Rare tumor with essentially no prior genomic data; druggable targets identified in all 9 cases; small N expected for this entity; J Pathol is high-quality peer-reviewed source
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.